- Poster presentation
- Open Access
PReS-FINAL-2284: SLE and complement deficiencies: a French multicentric retrospective study
© Roland-Gosselin et al.; licensee BioMed Central Ltd. 2013
Published: 5 December 2013
Systemic lupus erythematosus (SLE) is a multifactorial disease. Rare causes of monogenic SLE have been described, including the complement deficiencies.
Our objectives were to collect clinical data and outcome of SLE patients associated to complement deficiency in a multicenter retrospective study.
We conducted a retrospective study within the French paediatric rheumatology society (SOFREMIP) in 2012-2013.to identify patients, with a confirmed deficiency of complement fraction.
Ten cases of SLE with complement deficiency were identified: 2 C1 deficiencies, 2 C2 deficiencies and 6 partial C4 deficiencies. The sex ratio (M/F) is 0/10. The disease onset occurred in childhood in 8 patients with 6 before the age of 10. The first symptoms were cutaneous in 7 children, articular for 2 children and psychiatric for 1 patient. All patients were positive for antinuclear antibodies whereas only half of them were positive for anti-dsDNA antibodies. Anti-Ro (SS-A) antibodies were strongly positive in 8 patients. Anti-phospholipidantibodies were presentin 6 patients. Over time, 5 patients developed a severe disease associated to renal failure (n = 2) or neurolupus (n = 3). Associated autoimmune diseases were found in 4 patients: hypothyroidism (n = 1), autoimmune hepatitis (n = 2), Sjögren syndrome (n = 1). Two children with C2 and C4 deficiency had severe bacterial infections.
Cutaneous or joint manifestations are the most common symptoms but life-threatening complications can occur in the context of C1 deficiency. Anti-SSA antibodies were frequent while anti-DNA are only found in half of the cases. Genetic characterization of complement deficiencies remains challenging. Next generation sequencing may be helpful to better diagnose these monogenic forms of lupus.
Disclosure of interest
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.